Is it too soon to start reporting HER2 genetic heterogeneity?
نویسندگان
چکیده
No wonder you activities are, reading will be always needed. It is not only to fulfil the duties that you need to finish in deadline time. Reading will encourage your mind and thoughts. Of course, reading will greatly develop your experiences about everything. Reading is it too soon to start reporting her2 genetic heterogeneity letters the editor letter is also a way as one of the collective books that gives many advantages. The advantages are not only for you, but for the other peoples with those meaningful benefits.
منابع مشابه
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.
CONTEXT Intratumoral heterogeneity of HER2 gene amplification has been well documented and represents subclonal diversity within the tumor. The reported incidence of intratumor HER2 amplification genetic heterogeneity ranges in the literature from approximately 5% to 30%. The presence of HER2 genetic heterogeneity may increase subjectivity in HER2 interpretation by the pathologist. OBJECTIVES...
متن کاملGenetic heterogeneity of HER2/Neu in breast carcinoma: a meta analysis
Both immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are accepted methods fordetermining clinical HER2 (or ERBB2) status. However, the reliability of IHC and FISH is questionable. The genetic heterogeneity (GH) of breast carcinoma is a major cause that makes its diagnosis and treatment far from being optimal. To clarify the impact of FISH and IHC testing on HER2 GH, a m...
متن کاملHER2-positive gastric cancer with paraaortic nodal metastasis successfully resected after chemotherapy with trastuzumab: a case report.
We report on a case of human epidermal growth factor receptor-2 (HER2)-positive gastric cancer with paraaortic lymph node metastasis. The patient (a 49-year-old female) received chemotherapy (capecitabine and cisplatin) plus molecular-targeted therapy (trastuzumab), followed by curative resection. Interestingly, the resected residual cancer was HER2-negative. Intra-tumor heterogeneity hinders m...
متن کاملAutomated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine Definitions of Genetic Heterogeneity in Breast Cancer Tissue
Human epidermal growth factor receptor 2 gene- (HER2-) targeted therapy for breast cancer relies primarily on HER2 overexpression established by immunohistochemistry (IHC) with borderline cases being further tested for amplification by fluorescence in situ hybridization (FISH). Manual interpretation of HER2 FISH is based on a limited number of cells and rather complex definitions of equivocal, ...
متن کاملQuantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneity.
Breast cancer (BC) is a heterogeneous tumor, and better understanding of its heterogeneity is essential to improving treatment effect. Quantum dot (QD)-based immunofluorescent nanotechnology (QD-IHC) for molecular pathology has potential advantages in delineating tumor heterogeneity. This potential is explored in this paper by QD-IHC imaging of HER2 and ER. BC heterogeneity can be displayed mor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Archives of pathology & laboratory medicine
دوره 134 2 شماره
صفحات -
تاریخ انتشار 2010